Should pregnant women be included in phase IV clinical drug trials?

Gerald G. Briggs; Janine E. Polifka; Katherine L. Wisner; Eric Gervais; Richard K. Miller; Anick Berard; Gideon Koren; Alicia Forinash; Craig V. Towers

doi:10.1016/j.ajog.2015.05.047

Should pregnant women be included in phase IV clinical drug trials?

Gerald G. Briggs, Janine E. Polifka, Katherine L. Wisner, Eric Gervais, Richard K. Miller, Anick Berard, Gideon Koren, Alicia Forinash, Craig V. Towers

Pharmacy Practice Department

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	810-815
Number of pages	6
Journal	American Journal of Obstetrics and Gynecology
Volume	213
Issue number	6
DOIs	https://doi.org/10.1016/j.ajog.2015.05.047
State	Published - 2015

ASJC Scopus Subject Areas

Obstetrics and Gynecology

Keywords

birth defects
developmental toxicity
drugs
phase IV clinical trials
pregnancy

Access to Document

10.1016/j.ajog.2015.05.047

Cite this

@article{6e947b9a101c4b1ca1c145e4e82739ff,

title = "Should pregnant women be included in phase IV clinical drug trials?",

keywords = "birth defects, developmental toxicity, drugs, phase IV clinical trials, pregnancy",

author = "Briggs, {Gerald G.} and Polifka, {Janine E.} and Wisner, {Katherine L.} and Eric Gervais and Miller, {Richard K.} and Anick Berard and Gideon Koren and Alicia Forinash and Towers, {Craig V.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

doi = "10.1016/j.ajog.2015.05.047",

language = "English",

volume = "213",

pages = "810--815",

journal = "American Journal of Obstetrics and Gynecology",